Abstract: A spherical particle comprising decellularized omentum being between 1 nM-300 ?M in diameter is disclosed. In some embodiments, the particle comprises biological cells. In other embodiments, the particle comprises a biomolecule. Uses of the particles are also disclosed.

Abstract: A spherical particle comprising decellularized omentum being between 1 nM-300 ?M in diameter is disclosed. In some embodiments, the particle comprises biological cells. In other embodiments, the particle comprises a biomolecule. Uses of the particles are also disclosed.

Abstract: Provided herein is a see-through transparent, stable, safe and (bio)degradable hydrogel-based particulate support medium, made of calcium alginate particles. The calcium alginate particles, or hybrid hydrogel particles, are characterized by a substantially homogeneous average particle size that ranges from 0.1 micrometer to 5 micrometer.

Abstract: A spherical particle comprising decellularized omentum being between 1 nM-300 ?M in diameter is disclosed. In some embodiments, the particle comprises biological cells. In other embodiments, the particle comprises a biomolecule. Uses of the particles are also disclosed.

Abstract: The present invention relates to activatable toxin complexes which include a cleavable inhibitory peptide. More specifically, the complexes comprise a cell targeting domain, a toxin catalytic domain, a specific protease cleavage site and an inhibitory peptide domain. The inhibitory peptide prevents the catalytic domain from exerting toxic effects until its release from the complex by the action of a protease, such a viral protease, at the protease cleavage site. Further provided are pharmaceutical compositions comprising the complexes and use thereof for treating infections and malignant disease.

Abstract: The present invention relates to activatable toxin complexes which include a cleavable inhibitory peptide. More specifically, the complexes comprise a cell targeting domain, a toxin catalytic domain, a specific protease cleavage site and an inhibitory peptide domain. The inhibitory peptide prevents the catalytic domain from exerting toxic effects until its release from the complex by the action of a protease, such a viral protease, at the protease cleavage site. Further provided are pharmaceutical compositions comprising the complexes and use thereof for treating infections and malignant disease.